Why the study?
Does amlodipine mask the biochemical diagnosis of Conn's syndrome in patients with primary aldosteronism?
Does amlodipine mask the biochemical diagnosis of Conn's syndrome in patients with primary aldosteronism?
Calcium-channel blockers like amlodipine can mask the biochemical diagnosis of Conn's syndrome, potentially leading to under-diagnosis of this curable cause of hypertension.
Amlodipine may mask Conn's syndrome diagnosis; single case leaves open impact on primary aldosteronism screening.
A 30-year-old woman presented with hypertension and hypokalaemia, and was found to have primary aldosteronism due to a Conn's adenoma, whose removal cured the hypertension. Before surgery, the characteristic biochemical changes which enabled the diagnosis were completely masked by administration of a calcium-channel blocker, amlodipine. It is likely that widespread use of this class of drugs contributes to under-diagnosis of Conn's syndrome as a curable cause of hypertension.
No takes yet. Share an insight, caveat, or question.
Brown et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: